Top Markets
#1 Black Phoenix Black Phoenix +366.60%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +55.41%
#4 Gold Park Gold Park +55.06%
#5 Acurast Acurast +36.69%
#6 BasedHype BasedHype +29.98%
#7 Avantis Avantis +25.39%
#8 Cryptopia Cryptopia +22.04%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.42%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.20%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Kedudukan dalam Saham #40868
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Harga Saham
$0.02765
Disegerakkan terakhir: 2024-12-23
Modal Pasaran
$69.04K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Histogen Inc. (HSTO)

Kategori

Healthcare
Nisbah P/E bagi Histogen Inc. (HSTO)
Nisbah P/E pada August 2026 TTM: -0.01
Menurut laporan kewangan dan harga saham terkini Histogen Inc., nisbah P/E semasa (TTM) ialah -0.01. Pada akhir 2021, syarikat mempunyai nisbah P/E sebanyak -0.08.
Sejarah nisbah P/E bagi Histogen Inc. dari 2011 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -0.01 -80.67%
2022 -0.03 -70.37%
2021 -0.08 132.05%
2020 -0.04 -91.21%
2019 -0.42 42.30%
2018 -0.29 -61.58%
2017 -0.76 89.09%
2016 -0.40 -99.10%
2015 -44.41 -54.26%
2014 -97.09 59.73%
2013 -60.78 5,948.63%
2012 -1.00 37.11%
2011 -0.73 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -483,689.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -537,068.97%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -332,836.21%
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.